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Abstract Natural flavonoids such as genistein, kaempferol
and daidzein were previously found to be able to reduce effi-
ciency of glycosaminoglycan synthesis in cells of patients
suffering from mucopolysaccharidoses, inherited metabolic
diseases with often brain disease symptoms. This feature
was employed to test these compounds as potential drugs for
treatment other neuronopathic lysosomal storage disorders, in
which errors in sphingolipid metabolism occur. In this report,
on the basis of DNAmicroarray analyses and quantitative real
time PCR experiments, we present evidence that these com-
pounds modify expression of genes coding for enzymes re-
quired for metabolism of sphingolipids in human dermal fi-
broblasts (HDFa). Expression of several genes involved in
sphingolipid synthesis was impaired by tested flavonoids.
Therefore, it is tempting to speculate that they may be consid-
ered as potential drugs in treatment of LSD, in which accu-
mulation of sphingolipids, especially glycosphingolipids, oc-
curs. Nevertheless, further studies on more advances models
are required to test this hypothesis and to assess a therapeutic
potential for flavonoids in this group of metabolic brain
diseases.
Keywords Gene expression regulation . Flavonoid .
Lysosomal storage disease . Sphingolipidmetabolism
Introduction
Sphingolipids are ubiquitous components of mammalian
cell membranes. Their derivatives, glycosphingolipids
(GSLs), constitute a complex group modified by the ad-
dition of a carbohydrate unit. GSLs may be divided in two
major sets, represented by glucosylceramides (GlcCers)
and galactosylceramides (GalCers). Dominant type of
glucosylceramides, i.e. gangliosides are the major
glycoconjugates found in the nervous system (Schnaar
2005), while galactosylceramides have a much more re-
stricted distribution and are generally confined to myelin
and kidney (Schnaar 2009). The essential role of these
macromolecules is defined by the fact that defects in
genes encoding enzymes of both biosynthesis and degra-
dation of GSLs result in many severe metabolic disorders.
Inborn errors of GSL biosynthesis are at low frequency and
result in lethality with a failure of embryos to develop beyond
gastrulation (Yamashita et al. 1999), severe epilepsy syn-
drome (Simpson et al. 2004), or spastic paraplegia (Boukhris
et al. 2013). De novo biosynthesis of GSL competes with their
formation by salvage pathways using sphingolipid fragments
released from the lysosomal compartments. Depending on the
cell type, 50 - 90% of glycosphingolipids are derived from the
salvage pathways (Gillard et al. 1998; Tettamanti et al. 2003).
In contrast to sparse GSL biosynthetic diseases, there is a
relatively large group found to be an outcome of inappropriate
macromolecule catabolism, caused by inherited failure in
genes encoding lysosomal proteins. GSLs are degraded along
a strictly sequential pathway in humans, and for almost every
degradation step, a disease has been described in which the
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correlated enzyme or activator protein is defective. Lysosomal
accumulation of GSLs occurs predominantly in cells and or-
gans that have the highest rates of biosynthesis or uptake of
the undegradable sphingolipids and their precursors (Schultz
et al. 2011). Such massive accumulation prevents lysosomal
function, blocks signaling cascades dependent on Akt-mTOR
and Erk (Takamura et al. 2008), and inhibits nutrition delivery
through the endolysosomal system, leading to a state of cellu-
lar starvation (Jeyakumar et al. 2009).
GLS degradation process occurs in acidophilic cell com-
partment, endosomal/lysosomal system. Defects in GLS deg-
radation can lead to lysosomal storage disorders (LSDs).
Sphingolipidoses are a subgroup of LSDs involving accumu-
lation of sphingolipids and glycosphingolipids (Kolter and
Sandhoff 2006). They all occur through two distinct mecha-
nisms of metabolism, defects in biosynthesis or degradation
(Platt et al. 2012). One of several factors contributing to the
molecular pathogenesis and clinical form of LSDs is the level
of residual catabolic activity. Correlation between functional
residual catabolic activity and the progression of the lipid
storage disorder (Conzelmann and Sandhoff 1983) was basi-
cally confirmed for different clinical forms of diseases such as
metachromatic leukodystrophy (Leinekugel et al. 1992; Tan
et al. 2010), GM2-gangliosidosis (Leinekugel et al. 1992),
Gaucher disease (Gieselmann 2005) and Niemann-Pick type
A and B diseases (Ferlinz et al. 1995).
Sphingolipid accumulation also occurs in a group of LSDs
in which the primary issue is not a lack of a degradation
enzyme. Mostly these diseases are associated with problems
with trafficking and fusion in the endocytic system, leading to
secondary storage of GSLs (Platt et al. 2012). Niemann-Pick
type C (NPC), a disease thought to be mainly a disorder of
cholesterol transport from the lysosome is an extreme example
of this (Rosenbaum and Maxfield 2011).
Among several ways of treatment for LSDs, most ef-
fective is enzyme replacement therapy (ERT) (Brady
2006; Lim-Melia and Kronn 2009). Currently, only seven
from more than 50 lysosomal disorders are treated with
ERT, namely, Gaucher disease, Fabry disease, Pompe disease
and mucopolysaccharidosis types I, II, IVA and VI (Lim-
Melia and Kronn 2009; Rohrbach and Clarke 2007;
Tomatsu et al. 2014). Although such a recombinant enzyme
can be delivered to most tissues and organs, it cannot cross the
blood–brain-barrier (BBB), and thus, ERT is not effective in
treatment of neurological symptoms. Despite the great prog-
ress which has been made over the past 20 years, we still lack
satisfactory therapies for lysosomal brain diseases.
Until now, only two of LSDs belonging to sphingolipidosis
subgroup, Gaucher disease and Fabry disease, can be treated
with ERT (Banikazemi et al. 2007; Pastores et al. 2005;
Pastores 2010; Tajima et al. 2009). Moreover, an alternative
treatment of Gaucher disease is available, which is based on
reduction of the substrate synthesis (Hollak et al. 2009).
Besides, it was demonstrated that genistein (5, 7-dihydroxy-
3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one) can signifi-
cantly reduce efficiency of synthesis of glycosaminoglycans
(GAGs), compounds that accumulate inmucopolysaccharidoses
(MPSs) (Piotrowska et al. 2006). The mechanism of action of
genistein is based on inhibition of phosphorylation of the epi-
dermal growth factor receptor (EGFR) (Jakobkiewicz-Banecka
et al. 2009). As it was shown previously genistein and other
flavonoids have also significant impact on expression pattern
of genes coding for lysosome metabolism and macromolecule
degradation proteins, by the influence of the TFEB regulatory
pathway (Moskot et al. 2014; Sardiello et al. 2009). Effects of
flavonoids on GAG synthesis and storage, as well as on global
gene expression, reported recently (Moskot et al. 2015), re-
vealed that these compounds caused effective reduction in levels
of GAG production in fibroblasts, and induced remarkable al-
terations in profiles of transcripts derived from genes coding for
enzymes involved in GAG metabolism and from many other
genes. Transcriptomic analyses indicated that, despite certain
similarities, there are significant differences between effects of
the tested flavonoids (genistein, kaempferol and daidzein used
alone, and in combinations) on global gene expression patterns
in cells. Moreover, these studies revealed that among the tested
compounds, genistein (an isoflavone), kaempferol (a flavonol)
and a mixture of these two flavonoids had the most pronounced
effects on the regulation of genes’ activities. Interestingly, effects
of the mixture of genistein and kaempferol were stronger that
those revealed by any of these flavonoids used alone (Moskot
et al. 2015). It is worth tomention that these flavonoids can cross
the BBB (Tsai 2005), what makes reasonable considering these
compounds as potentially useful in the optimization of treatment
for neuronopathic forms of LSDs, including sphingolipidoses.
Therefore, the aim of this work was to assess effects of flavo-
noids on expression of genes involved in sphingolipid
metabolism.
Materials and methods
Cell cultures of fibroblasts
Cell line of Human Dermal Fibroblasts (HDFa) was obtained
from the Cascade Biologics, Portland, OR, USA. Fibroblasts
were cultured from cryo-preserved cells in Dulbecco’s modi-
fied Eagle’s medium (DMEM) containing 10 % fetal bovine
serum (FBS) and 1 % antibiotic/antimycotic solution (Sigma-
Aldrich, MO, USA) at 37 °C in a humidified atmosphere of
5 % CO2. Genistein was synthetized at the Pharmaceutical
Research Institute (Warsaw, Poland), while kaempferol and
daidzein were obtained from Sigma-Aldrich (Steinheim,
Germany). Tested flavonoids were dissolved in dimethyl sulf-
oxide (DMSO) and added to the indicated final concentra-
tions, as determined in previous studies (Kloska et al. 2011;
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Piotrowska et al. 2006), to cell cultures. For experimental
procedures, cells were plated to a confluence of approximately
80 %. After overnight incubation, culture medium was re-
placed with fresh medium either flavonoid-free one, contain-
ing DMSO at a final concentration of 0.05% (control, Ctrl), or
the one supplemented with appropriate amounts of tested fla-
vonoids. The experimental treatment was carried out for 1, 24
and 48 h period.
RNA extraction
Total RNAwas extracted from cells using the High Pure RNA
Isolation Kit (Roche Applied Science, Indianapolis, USA)
following the manufacturer’s instructions. The quality and
quantity of each RNA sample was evaluated using the RNA
6000 Nano Assay on the Agilent 2100 Bioanalyser (Agilent
Technologies Inc., USA).
Microarray assays for mRNA analysis
Abundance of various mRNAs was measured using
Illumina’s Human HT-12 v3 Expression BeadChips
(Illumina Inc., CA, USA) [http://www.illumina.com/
Documents/products/datasheets/datasheet_humanht_12.pdf].
The BeadChip supports highly efficient whole-genome tran-
scriptional studies targeting more than 25,000 genes with
more than 48,000 probes. Probes were designed using the
RefSeq and the UniGene databases. Illumina TotalPrep
RNA Amplification Kit (Ambion, TX, USA) was used in
order to amplify total input RNA. Following linear
Table 1 Assay ID, primers and probes used for real-time quantitative Reverse Transcription PCR validation of selected genes
Target Transcript Reference gene Primers Amplicon Probe
Name/Length
Sequence ID
Sequence/Length or assay ID Length (nt) Region
GSL metabolism
genes
ARSA/1900
ENST00000395624
PGK1, TFRC Assay ID: 104759 96 Exons 4-5
932
–
ASAH1/2618
NM_177924.3
GAPDH, TBP F: ACAGTTCTGGAAAATAGCACAAGT/25
R: GGTTGCCTCCCAGGATAAAG/20
98 Exons 9-10
1074
# 57
CLN8/7185
NM_018941.3
GAPDH, TBP F: TCTCCAAGCTGGCCACTATC/20
R: CTGGTTGAGCTTCCAAAACAG/21
127 Exons 2-3
848
# 80
GBA1/2324
NM_000157.3
GAPDH, TBP F: CTTTGTCGACAGTCCCATCA/20
R: CCCTCAGGAATGAACTTGCT/20
102 Exons 9-10
1471
# 9
GLA/1418
NM_000169.2
GAPDH, TBP F: GAAGAGCCAGATTCCTGCAT/20
R: TCCTTCCAGCCTTCTGAGAC/20
77 Exons 1-2
302
# 53
GM2A/3690
NM_000405.4
GAPDH, TBP F: GTGTCCCCCTGAGTTCTCCT/20
R: GTCTGTGCATGGGATCTTGA/20
86 Exons 2-3
384
# 10
HEXA/2737
NM_000520
PGK1, TFRC Assay ID: 117642 63 Exons 5-6
1075
–
HEXB/2437
NM_000520.4
GAPDH, TBP F: CCCCTGGCATTTGAAGGTA/19
R: ACATATTCTCCCCACATACAAGC/23
127 Exons 12-13
1534
# 22
NEU1/2045
ENST00000375631
PGK1, TFRC Assay ID: 126666 102 Exons 2-3
483
–
NPC1/4741
NM_000271
PGK1, TFRC Assay ID: 111681 74 Exons 13-14
2270
–
NPC2/921
NM_006432.3
GAPDH, TBP F: CAGTGAAAAGCGAATATCCCTCTA/24
R: GAGATGAGAAACGATCTGTACTGG/24
111 Exons 3-4-5
472, 549
# 3
PPT1/2195
NM_001142604.1
GAPDH, TBP F: CCAAGGAAACCATTCCCTTAC/21
R: GATGGTCCCCTTCTGTAGCC/20
114 Exons 5-6
720
# 45
SMPD1/2482
NM_000543.4
GAPDH, TBP F: CTATGAAGCGATGGCCAAG/19
R: TGGGGAAAGAGCATAGAACC/20
91 Exons 2-3
1214
# 71
SUMF1/2159
NM_182760
PGK1, TFRC Assay ID: 116675 85 Exons 8-9
1051
–
Other GAPDH/1338
NM_002046
Reference gene F: CTCTGCTCCTCCTGTTCGAC/20
R: GCCCAATACGACCAAATCC/19
119 Exons 1-2-3
126
# GAPDH
PGK1/4887
NM_000291
Reference gene Assay ID: 102083 78 Exons 4-5
585
# PGK1
TBP/1851
NM_003194
Reference gene F: TGAATCTTGGTTGTAAACTTGACC/24
R: CTCATGATTACCGCAGCAAA/20
94 Exons 4-5
824
# TBP
TFRC/5032
ENST00000392396
Reference gene Assay ID: 102095 69 Exons 14-15
1820
# TFRC
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amplification by T7 RNA polymerase, in vitro synthesized,
biotin-labeled cRNAwas applied to the BeadChip for hybrid-
ization according to the manufacturer’s instructions.
BeadChips were scanned using an Illumina BeadArray
Reader and the Bead Scan Software (Illumina Inc., CA,
USA). The quality of microarray data was controlled by ex-
amining raw and adjusted intensity histograms. The detection
scores (detection p value) were used to determine expressions
of each gene using BeadStudio software 2.3.4 (Illumina Inc.,
CA, USA), which was computed based on Z-values of a gene
relative to the Z-value of negative controls on expression chip.
Normalization of gene expression data were done by the
GeneSping software 7.3.1 (Agilent Technologies, CA, USA)
as the value normalized per chip and per gene with median.
Data extraction and statistical analysis
Illumina’s Human HT-12v4 Expression BeadChips (Illumina
Inc., USA) were used for the microarray analysis of three
biological replicates. The assay performance, data extraction
and statistical analysis were performed as previously de-
scribed (Moskot et al. 2014). Gene expression data have been
deposited in the NCBI’s Gene Expression Omnibus (GEO,
http:www.ncbi.nlm.nih.gov/geo, GEO Series accession
number GSE43692 and GSE34074) according to the
MIAME standards. The comparison of relative fold change
of gene expression levels between flavonoid-treated and non-
treated cells was performed. Sphingolipid metabolism path-
ways were defined according to the KEGG annotation
(Kanehisa et al. 2006) (Path: hsa00600, hsa00601, hsa00603
and hsa00604) and AmiGO (GO:0030148, GO:0006665 and
GO:0030149).
Quantitative real-time RT-PCR for mRNA analysis
Quantitative real-time Reverse Transcription PCR (real-time
qRT-PCR) was performed to measure the mRNA levels of the
studied genes using the LightCycler® System 480 (Roche
Applied Science, Indianapolis, USA). Total RNA was
reverse-transcribed into cDNA using Transcriptor First
Strand cDNA Synthesis Kit (Roche Applied Science, IN,
USA), according to the manufacturer’s instructions.
Quantification of mRNA levels was conducted using
LightCycler TaqMan Master (Roche Applied Science, IN,
USA). In case of ARSA, ASAH1, HEXA, NEU1, NPC1 and
SUMF1 genes real-time qRT-PCR analysis was performed
using Real Time ready Custom Panel (cat no. 05532914001,
config. no. 90014731, Roche Applied Science, Indianapolis,
USA) and LightCyclerH 480 Probes Master (Roche Applied
Science, Indianapolis, USA), as determined in previous study
(Moskot et al. 2015). However, primers utilized for specific
amplification of the CLN8, GBA1, GLA, GM2A, HEXB,
NPC2, PPT1 and SMPD1 genes were obtained from
Thermo Fisher Scientific GmbH. The 2-ΔΔct method was used
to determine the relative gene transcript levels after normali-
zation to the reference gene coding for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, Ref1), TATA box bind-
ing protein (TBP, Ref2), phosphoglycerate kinase 1 (PGK1,
Ref1), and transferrin receptor (TFRC, Ref2). Primers and
probes of reference genes GAPDH (NM_002046), PGK1
(NM_000291) , TBP (NM_003194.4) and TFRC
(ENST00000392396) were bought from Roche Applied
Science, IN, USA. Negative controls were tested in parallel.
Primers, probes and assay ID are described in Table 1.
Results
Profiling of expression of genes involved in sphingolipid
metabolism with microarrays
Microarray analysis of transcripts derived from genes coding
for sphingolipid metabolism enzymes showed those which
expression was identified as different by at least 0.7 and 1.3
fold change (p < 0.05) following flavonoids’ exposure in re-
lation to control of non-treated samples of human dermal
Fig. 1 Number of genes revealing altered expression in response to
various flavonoids’ treatment type (genistein, kaempferol, daidzein, and
mixtures of them as stated), identified in the microarray analysis of GSL
metabolism associated transcripts (0.7 ≥ FC ≥ 1.3) of HDFa cells, with the
p-value <0.05, and n ≥ 3
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Table 3 Expression patterns of GSL metabolism-associated genes in
flavonoids (at least in one experimental condition: 100 μM genistein,
100 μM kaempferol, genistein-kaempferol of 30 μM each, 100 μM
daidzein or genistein-daidzein of 30 μM each, for 24 and/or 48 h)
treated HDFa fibroblasts analyzed with microarray. Values represent
fold change and denote differences for samples treated with tested
compounds or their mixture, against untreated samples
Gene symbol Genistein Kaempferol Genistein + Kaempferol Daidzein Genistein + Daidzein
Time of exposure [h]
24 48 24 48 24 48 24 48 24 48
A4GALT 1.4 ± 0.1 1.7 ± 0.1 1.5 ± 0.1 1.4 ± 0.0
ACER3 1.4 ± 0.4 0.7 ± 0.1
ARSA 1.3 ± 0.2 1.5 ± 0.2 1.3 ± 0.1 1.3 ± 0.1 1.3 ± 0.2
ASAH1 1.7 ± 0.8 1.5 ± 0.3 1.9 ± 0.1 1.3 ± 0.0 1.5 ± 0.1 1.8 ± 0.9
B3GALNT1 1.4 ± 0.1
B3GNT1 1.6 ± 0.1 1.3 ± 0.1 1.5 ± 0.2
B3GNT2 0.6 ± 0.0 0.5 ± 0.0 1.6 ± 0.2 1.7 ± 0.1 1.9 ± 0.5
B3GNT5 1.4 ± 0.0
B4GALT1 1.5 ± 0.2 1.4 ± 0.1
B4GALT4 0.7 ± 0.0
B4GALT6 1.7 ± 0.0 0.7 ± 0.0
CLN8 1.9 ± 0.2 3.3 ± 1.1 1.5 ± 0.3
COL4A3BP 1.5 ± 0.4 1.6 ± 0.4 2.2 ± 0.1 1.8 ± 0.3 1.7 ± 0.1 1.3 ± 0.2
CSNK1G2 1.4 ± 0.0
CYR61 1.4 ± 0.3
ELOVL1 0.6 ± 0.1 0.6 ± 0.1 0.7 ± 0.0 0.6 ± 0.1
FUT4 1.4 ± 0.2 1.3 ± 0.1
FUT6 1.4 ± 0.0
GALC 1.7 ± 0.2 1.3 ± 0.2
GBA1 1.4 ± 0.4 1.6 ± 0.2 1.4 ± 0.0 1.5 ± 0.2 1.6 ± 0.2
GBA2 1.3 ± 0.3
GBGT1 1.9 ± 0.2 1.9 ± 0.3 1.6 ± 0.2 1.9 ± 0.4 1.3 ± 0.3 1.5 ± 0.2
GLA 1.5 ± 0.1 1.4 ± 0.0 1.3 ± 0.0
GM2A 1.7 ± 0.4 1.5 ± 0.6
HEXA 1.4 ± 0.2 1.6 ± 0.4 1.4 ± 0.3 1.5 ± 0.3 1.7 ± 0.1
HEXB 1.4 ± 0.1
KDSR 1.8 ± 0.5 1.6 ± 0.6 1.5 ± 0.3 1.5 ± 0.0
LARGE 1.6 ± 0.2 1.3 ± 0.0 1.7 ± 0.2 1.4 ± 0.1
LASS2 1.4 ± 0.2
NAGA 0.6 ± 0.0 1.4 ± 0.5
NEU1 2.9 ± 0.4 2.5 ± 0.3 1.6 ± 0.1 1.5 ± 0.1 2.3 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.7 ± 0.2 2.2 ± 0.4
NPC1 1.5 ± 0.4 2.3 ± 0.4 1.4 ± 0.4 1.6 ± 0.1 1.4 ± 0.2
NPC2 1.4 ± 0.1 1.4 ± 0.1 1.3 ± 0.1 1.4 ± 0.1
PPAP2A 1.4 ± 0.6 1.6 ± 0.5 2.0 ± 0.5 3.6 ± 0.1 2.7 ± 0.2 4.9 ± 0.5 1.5 ± 0.1 1.9 ± 0.1 1.6 ± 0.2 2.0 ± 0.5
PPAP2C 1.7 ± 0.0
PPT1 1.4 ± 0.2 1.4 ± 0.1 1.4 ± 0.1
PRKCD 0.7 ± 0.0
PRKD1 1.4 ± 0.1
SGMS1 0.7 ± 0.1 1.3 ± 0.3 1.6 ± 0.1 1.5 ± 0.0
SGMS2 0.7 ± 0.0
SGPL1 0.7 ± 0.1
SGPP1 0.6 ± 0.1 1.4 ± 0.4
SLC33A1 1.7 ± 0.1 1.3 ± 0.1 1.5 ± 0.3
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fibroblasts (HDFa). As discovered in five independent assays,
most compound-dependent changes among 121 genes of GSL
metabolism occurred at 100 μM kaempferol-treated cells for
48 h (i.e. 29, with 19 up- and 10 down-regulated genes) as
shown in Fig. 1. For 24 h treatment with particular flavonoids,
27 genes (i.e. 18 and 9 with a greater than 2-fold increase and
decrease in expression, respectively) had modulated expres-
sion for 100 μM kaempferol, 20 revealed up-regulation for
100 μM genistein, while 9 were down-regulated for 100 μM
kaempferol. After 48 h of exposition to various flavonoids, we
found 21 transcripts to be remarkably up-regulated by genis-
tein and kaempferol mix treatment, while ten were found to be
down-regulated by 100 μM kaempferol.
Studying carefully the gene expression levels modulated
after 24 h of treatment with tested flavonoids, we found one
transcript (i.e. PPAP2A) in common between all tested condi-
tions, while 5 mRNAs were up-regulated after 48 h of incu-
bation with flavonoids (i.e. CL4A3BP, NEU1, PPAP2A,
SMPDL3A and SUMF1). PPAP2A mRNA was therefore in-
cluded in both 24 and 48 h time course sets. Considering
particular flavonoids for both 24 and 48 h treatment, among
genes with positively regulated activity, we found 14 for
100 μM genistein (i.e. ARSA, ASAH1, COL4A3BP, GBA1,
GBGNT1, GM2A, HEXA, KDSR, NEU1, NPC1, PPAP2A,
SMPD1, SMPDL3A and SUMF1), 13 for 100 μM kaempferol
(i.e. CLN8, GLA, HEXA, KDSR, LARGE, NEU1, NPC1,
PPAP2A, SMPDL3A, SPHK1, SPHK2, ST3GAL1 and
SUMF1), 5 for genistein and kaempferol mixture (i.e. GBA1,
GBGT1, PPAP2A, SMPDL3A and SUMF1), 3 for 100 μM
daidzein (i.e. ASAH1,NEU1 and PPAP2A), and 3 for genistein
and daidzein mixture (i.e. GBGT1, NEU1 and PPAP2A).
Taking on account genes with a decreased expression, five
transcripts were found to be modulated after both 24 and
48 h of treatment with 100 μM kaempferol (i.e. B3GNT1,
ELOVL1, SPTLC2, ST3GAL6 and ST6GALNAC5), while
one for genistein and kaempferol mix (i.e. ST3GAL6).
When looking at studied conditions, i.e. at least in one
experimental state we found several transcripts with increased
and/or decreased expression, belonging to various regulation
modules with corresponding overlap of some genes between
the sets of regulatory processes (Tables 2 and 3). Among those
genes we determined several transcripts (i.e. ARSA, ASAH1,
CLN8, GALC, GBA1, GLA, GM2A, HEXA, HEXB, NAGA,
NEU1, NPC1, NPC2, PPT1, SMPD1 and SUMF1) being as-
sociated with sphingolipids’ disorders (Table 4).
Real-time qRT-PCR analysis of expression of genes
involved in sphingolipid metabolism
Real-time quantitative Reverse Transcription PCR (real-time
qRT-PCR) was used to confirm a set of gene expression
changes observed in the microarray analysis. To choose the
most stable genes as internal references for real-time qRT-
PCR data normalization, two candidates - GAPDH (Ref1)
and TBP (Ref2) for CLN8, GBA1, GLA, GM2A, HEXB,
NPC2, PPT1 and SMPD1, while other two - PGK1 (Ref1)
and TFRC (Ref2) for ARSA, ASAH1, HEXA, NEU1, NPC1,
and SUMF1 genes, respectively, were selected according to
Table 3 (continued)
Gene symbol Genistein Kaempferol Genistein + Kaempferol Daidzein Genistein + Daidzein
Time of exposure [h]
24 48 24 48 24 48 24 48 24 48
SMPD1 1.4 ± 0.2 1.7 ± 0.2 1.3 ± 0.1 1.5 ± 0.1 1.4 ± 0.1
SMPD2 1.6 ± 0.0
SMPDL3A 1.5 ± 0.3 2.3 ± 0.8 1.7 ± 0.1 2.1 ± 0.1 1.5 ± 0.2 2.6 ± 0.2 1.3 ± 0.1 1.6 ± 0.3
SPHK1 2.2 ± 0.1 2.0 ± 0.3 0.6 ± 0.0
SPHK2 1.6 ± 0.0 1.4 ± 0.0 1.3 ± 0.1
SPTLC1 1.3 ± 0.2 1.8 ± 0.4 0.6 ± 0.0
SPTLC2 0.5 ± 0.1 0.7 ± 0.1 0.7 ± 0.1
ST3GAL1 1.4 ± 0.2 1.5 ± 0.3
ST3GAL2 0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.1
ST3GAL3 0.6 ± 0.1 0,6 ± 0,0
ST3GAL4 0.7 ± 0.2 0.7 ± 0.1 0.5 ± 0.0 0.6 ± 0.0 0.7 ± 0.1
ST3GAL5 1.3 ± 0.1 1.9 ± 0.2 2.7 ± 0.1 1.7 ± 0.2 1.3 ± 0.1 1.7 ± 0.3
ST3GAL6 0.7 ± 0.2 0.6 ± 0.2 0.5 ± 0.0 0.7 ± 0.1 0.4 ± 0.1
ST6GALNAC5 0.5 ± 0.0 0.5 ± 0.1 0.5 ± 0.0 0.5 ± 0.1
SUMF1 1.6 ± 0.2 1.7 ± 0.3 1.4 ± 0.1 1.6 ± 0.1 1.4 ± 0.1 1.7 ± 0.1 1.5 ± 0.1 1.5 ± 0.2
UGCG 0.6 ± 0.2 1.4 ± 0.1
Metab Brain Dis (2015) 30:1257–1267 1263
their expression levels detected in the microarray studies.
From 59 GSL metabolism genes regulated under tested con-
ditions (Table 3), 14 from 16 genes coding for enzymes in-
volved in glycosphingolipid metabolism disorders (as shown
in Table 4) were experimentally validated (Fig. 2). For the two
other genes, GALC and NAGA designing of intron spanning
primers was not possible, therefore they were not included in
the analysis. Basically, the real-time qRT-PCR and microarray
methods showed a good agreement on regulated genes
(Fig. 2).
Discussion
Since molecular mechanisms of LSDs are rather well under-
stood (relative to many other diseases of this nature), and as
they were among the first genetic diseases for which effective
- at least to some extent - treatment became possible, these
disorders may be considered as models in inherited metabolic
diseases. There are several LSDs, in which accumulation and
storage of sphingolipids occur as the primary cause of symp-
toms (Sandhoff 2013).
In the light of problems with crossing BBB, it appears
crucial to look for potential drugs that could be used in path-
ological sphingolipid storage. One group of such potential
drugs are flavonoids, such as genistein (an isoflavone),
kaempferol (a flavonol) and daidzein (an isoflavone), com-
pounds which were reported previously to partially inhibit
GAG synthesis and to reduce GAG storage in fibroblasts de-
rived from patients suffering from mucopolysaccharidoses,
metabolic disorders belonging to LSDs (Arfi et al. 2010;
Kloska et al. 2011). Since potentially many genes involved
in synthesis of various biologically active molecules could be
controlled by the EGF-dependent pathways, and at the same
time some other transcripts regulating lysosomal administra-
tion are regulated by the TFEB pathway, we asked if previ-
ously selected and studied flavonoids can also influence ex-
pression of genes coding for enzymes required for
sphingolipid metabolism.
In this report, we demonstrate that flavonoids influence
expression of dozens of genes involved in sphingolipid me-
tabolism. In general, the DNA microarray analysis indicated
that kaempferol, genistein and mix of these two compounds
profiled the expression of the greatest number of genes
Table 4 GSL metabolism genes associated with sphingolipids’
disorders of HDFa cells with modulated expression after 24 and/or 48 h
treatment with various flavonoids (100 μM genistein, 100 μM
kaempferol, genistein-kaempferol of 30 μM each, 100 μM daidzein and
genistein-daidzein of 30 μM each) identified in the microarray analysis
(0.7 ≥ FC ≥ 1.3, n ≥ 3, with the p-value <0.05)
Genes GSL metabolism disorder Compounds
Genistein Kaempferol Genistein + Kaempferol Daidzein Genistein + Daidzein
ARSA Metachromatic leukodystrophy (MLD) √ √ √ √
ASAH1 Farber lipogranulomatosis √ √ √ √
CLN8 Neuronal ceroid lipofuscinosis, LINCL variant √ √
Progressive myoclonic epilepsy (PME/EPM)
GALC Krabbe disease √ √
GBA1 Gaucher disease √ √ √
Lewy body dementia (LBD)
Progressive myoclonic epilepsy (PME/EPM)
GLA Fabry disease √ √
GM2A Tay-Sachs disease variant AB (GM2 gangliosidosis
variant AB)
√
HEXA Tay-Sachs disease (GM2 gangliosidosis type I) √ √ √
HEXB Sandhoff disease (GM2 gangliosidosis type II) √
NAGA Schindler/Kanzaki disease √
NEU1 Sialidosis/Mucolipidosis I √ √ √ √ √
Galactosialidosis
Progressive myoclonic epilepsy (PME/EPM)
NPC1 Niemann-Pick disease type C1 (NPC1) √ √ √
NPC2 Niemann-Pick disease type C2 (NPC2) √ √ √ √
PPT1 Neuronal ceroid lipofuscinosis (CLN1, INCL) √
Progressive myoclonic epilepsy (PME/EPM)
SMPD1 Niemann-Pick disease (NPD) type A and B √ √ √ √
SUMF1 Multiple sulfatase deficiency (MSD) √ √ √ √ √
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Fig. 2 Effect of genistein (100 μM, a), kaempferol (100 μM, b), andmix
of genistein and kaempferol (30 μM each, c) on mRNA level of selected
genes up-regulated with an expression ratio greater than 1.3-fold, and
with statistical significance set at p ≤ 0.05, involved in sphingolipid
metabolism in HDFa cells after 24 h of treatment. Two types of
analyses were made: microarray gene expression studies (white
columns) and real-time qRT-PCRs (light and dark grey columns), where
the data represent averaged values ±SD from n ≥ 3 and denote significant
differences for samples treated with tested compound/s against non-
treated samples, with respect to reference genes of constant expression
level: GAPDH (Ref 1) and TBP (Ref 2) for CLN8, GBA1, GLA, GM2A,
HEXB,NPC2, PPT1 and SMPD1, while PGK1 (Ref 1) and TFRC (Ref 2)
for ARSA, ASAH1, HEXA, NEU1, NPC1, and SUMF1, respectively.
*Results based on raw data from Moskot et al. (2015)
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(Fig. 1). When looking at particular studied conditions, we
found numerous of transcripts with altered expression belong-
ing to various regulationmodules, such as: GSL biosynthesis -
globo series, GSL biosynthesis - lacto and neolacto series,
GSL biosynthesis - ganglio series, lactosylceramide biosyn-
thesis, glycerolipid metabolism, ceramide biosynthesis, sphin-
gosine biosynthesis, sphingosine degradation, other
sphingolipid metabolism genes, intracellular trafficking or fu-
sion GSL catabolic enzyme modification, with corresponding
overlap of genes between these sets of regulatory processes
(Table 2). Additionally, we conclude that 59 among 121 genes
of GSL metabolism were regulated at least in one experimen-
tal condition (Table 3). What is interesting, 16 genes from
them are associated with well-known sphingolipids disorders
(Table 4).
Previous studies indicated that flavonoids, particularly ge-
nistein and kaempferol, modified expression of genes coding
for metabolism of GAGs in a specific manner. Namely, ex-
pression of many (but not all) genes which products are in-
volved in synthesis of GAGs were down-regulated while a
few were up-regulated, whereas vast majority of transcripts
derived from genes coding for GAG-degradation enzymes
were more abundant after treatment with genistein,
kaempferol or their mixture (Moskot et al. 2014). In the case
of GSL metabolism, the picture is more complicated. In both
groups, up- and down-regulated by flavonoids, there are genes
coding for enzymes involved in synthesis and degradation of
particular lipids’ derivatives. Moreover, in each particular
pathway for production and degradation of specific class of
GSLs, there are always stimulated and inhibited genes coding
for enzymes operating in both opposite pathways. One might
predict that inhibition of a crucial step in synthesis of particu-
lar GSL may results in impairment of the whole process, even
if other steps are stimulates, according to the bottleneck mech-
anisms, i.e. the restriction of the efficiency of the whole path-
way by the slowest reaction. However, such a hypothesis re-
quires experimental verification.
It does not escape our attention that fibroblasts are not the
best models for genetic and biochemical changes in neurons,
while diseases caused by GSLs’ accumulation cause brain
dysfunctions. However, for in vitro experiments with the mi-
croarray technology, which allowed us to monitor expression
of many genes at the same time but which also require rela-
tively large amount of biochemically good quality material
isolated from actively growing cells, human fibroblasts ap-
peared to be the optimal choice. Other possible experimental
systems would have severe restrictions in the availability of
the material and viability of cells. Nevertheless, it is obvious
that any further studies which might lead to determination if
flavonoids can be considered as potential drugs for manage-
ment of GSL-storage diseases should involve either cultures
of cells types which are modelsmore closely resembling phys-
iology of the brain or animal models for particular diseases.
In summary, our results indicate that expression of several
genes involved in sphingolipid synthesis can be regulated by
tested flavonoids. Therefore, it is tempting to speculate that
they may be considered as potential drugs in treatment of
LSD, in which accumulation of sphingolipids, especially
glycosphingolipids, occurs. Nevertheless, further studies on
more advances models are required to test this hypothesis
and to assess a therapeutic potential of flavonoids in this group
of metabolic brain diseases.
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